For patients with high-risk solid tumors (Ewing’s sarcoma, neuroblastoma and rhabdomyosarcoma), standard therapies may not offer a complete cure. In an adult clinical trial, researchers are evaluating the safety and effectiveness of a dual-process cellular therapy approach. Parameswaran Hari, MD, hematologist/oncologist, is the principal investigator at Froedtert & the Medical College of Wisconsin Froedtert Hospital. (Children’s Hospital of Wisconsin also offers the trial for pediatric patients.)
After going through an immunosuppression regimen, patients receive an allogeneic transplant of stem cells from a haploidentical donor — a family member with half-matched cells. A week later, the patient receives another infusion from the same donor. The second infusion contains natural killer (NK) cells, the white blood cells that fight infection, act against cancer cells and help new bone marrow stem cells grow. Researchers hope that using haploidentical donor cells will increase graft-versus-tumor effects, with the added benefit of allowing the donor’s immune system cells to more effectively attack the patient’s cancer. Eligible patients cannot be candidates for autologous or human leukocyte (HLA) matched sibling hematopoietic cell transplants.
For Our Referring Physicians:
Academic advantage of clinical trials
The Froedtert & MCW health network gives patients and their referring physicians a distinct advantage.
For more information or to refer a patient, call the Froedtert & MCW Clinical Trials Office at 414-805-8900, referencing protocol IIT-THAKAR-STIR. To view a list of all current adult cancer clinical trials, visit froedtert.com/clinicaltrials. Contact our physician liaison team for more information about our clinical trials or if you would be interested in meeting with any of the clinical trial team members.